Characteristics and Outcomes of Cancer Patients With Venous Thromboembolic Events After Treatment With Immune Checkpoint Inhibitors

*Department of Internal Medicine, The University of Texas Health Science Center

§Department of Gastroenterology, Hepatology and Nutrition, The University of Texas MD Anderson Cancer Center

†Department of Internal Medicine

‡Department of Gastroenterology and Hepatology, Baylor College of Medicine, Houston, TX

B.D. and V.G.R. are co-first authors.

Y.W. and A.T. are co-senior authors.

The study was conducted with approval from the Institutional Review Board at MD Anderson Cancer Center.

Informed consent from patients was waived for this study.

The data and material for this study are available for review.

A.S.T. and Y.W.: senior authors of the study; they developed the concept, designed the study, interpreted the results, ensured that data accuracy and integrity were preserved at all stages, agreed to be accountable for all aspects of the study, were in charge of the overall direction and planning of the study, and contributed to the writing of the manuscript, with input from all authors. V. G-R, B.D., and R.G.: collected the data for the study, conducted and interpreted the analysis, and wrote the manuscript. D.S., F.A., S.K.,J.L., R.A.: contributed to the data collection. All authors read and approved the final manuscript.

The datasets used and analyzed in this study are available from the corresponding author on reasonable request.

The authors declare no conflicts of interest.

Correspondence: Anusha Thomas, MD, Department of Gastroenterology, Hepatology and Nutrition, Unit 1466, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA. E-mail: [email protected].

Supplemental Digital Content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's website, www.amjclinicaloncology.com.

留言 (0)

沒有登入
gif